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Abstract
Background: Large animal models are important in atrial fibrillation (AF) research, as they can be used to study the
pathophysiology of AF and new therapeutic approaches. Unlike other animal models, horses spontaneously
develop AF and could therefore serve as a bona fide model in AF research. We therefore aimed to study the
electrical, functional and structural remodelling caused by chronic AF in a horse model.
Method: Nine female horses were included in the study, with six horses tachypaced into self-sustained AF and three
that served as a time-matched sham-operated control group. Acceleration in atrial fibrillatory rate (AFR), changes in
electrocardiographic and echocardiographic variables and response to medical treatment (flecainide 2mg/kg) were
recorded over a period of 2 months. At the end of the study, changes in ion channel expression and fibrosis were
measured and compared between the two groups.
Results: AFR increased from 299 ± 33 fibrillations per minute (fpm) to 376 ± 12 fpm (p < 0.05) and atrial function (active
left atrial fractional area change) decreased significantly during the study (p < 0.05). No changes were observed in heart
rate or ventricular function. The AF group had more atrial fibrosis compared to the control group (p < 0.05). No
differences in ion channel expression were observed.
Conclusion: Horses with induced AF show signs of atrial remodelling that are similar to humans and other animal
models.
Keywords: Animal model, Atrial fibrillation, Atrial fibrillatory rate, Chronic atrial fibrillation, Equine, Flecainide, Horse
Background
Atrial fibrillation (AF) remains the most important
arrhythmia in clinical practice, with a high morbidity,
mortality and economic burden on society (1). AF alters
the electrophysiology, the structure and the contractility
of the atrium – a process commonly known as atrial
remodelling. Atrial remodelling further promotes AF (2)
and impedes cardioversion to sinus rhythm (SR). Animal
models complement clinical studies by investigating the
underlying mechanisms leading to AF and its
maintenance. Furthermore, a good large animal model
could also indicate whether new antiarrhythmic drugs will
be useful in the clinic and report on potential side effects.
Models for AF research span ex vivo cellular studies to
larger animal models, yet the preference seems to have
shifted over the years toward: 1) large animal models, as
the AF mechanisms are highly complex and require a
proper substrate and 2) chronic AF models, as AF de-
velops over time and these changes are crucial for optimal
treatment (3).
Horses fulfil several requirements of a bona fide model
for AF studies; horses are large animals that are easy to
handle and many procedures can be performed without
sedation or anaesthesia. They have a high AF inducibility
(4, 5), and most importantly, spontaneously develop AF
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: rib@sund.ku.dk
1Department of Veterinary Clinical Sciences, Faculty of Health and Medical
Sciences, University of Copenhagen, Højbakkegaard Allé 5, 2630 Taastrup,
Denmark
Full list of author information is available at the end of the article
Hesselkilde et al. BMC Cardiovascular Disorders          (2019) 19:228 
https://doi.org/10.1186/s12872-019-1210-4
both with and without the presence of structural heart
disease. Furthermore, horses with chronic AF do not de-
velop heart failure, which facilitates long-term studies
(6). Horses have previously been suggested as an animal
model for AF studies and several studies have investi-
gated the short term effect of induced AF in horses (15
min – 7 days) (4, 5, 7–9) while only a few studies on
long-term AF exist (10, 11).
In order to establish the horse as an animal model, it
is important to document the effect of AF on electrical,
structural and contractile remodelling over time. The
aim of the study was therefore to develop a long-term
(55 days) horse model with tachypacing-induced AF.
Electrocardiography (ECG), echocardiography, histology
and molecular expression studies were performed in
order to evaluate temporal changes. We hypothesized
that horses with induced AF would develop electrical,
functional and structural remodelling, observed as
changes in atrial fibrillatory rate (AFR), reduced atrial
function and changes in ion channel expression and
atrial fibrosis, respectively.
Methods
Nine female Standardbred horses aged 4–17 years (10 ±
5 years), with a body weight between 408 and 572 kg
(474 ± 47 kg) were included in the study. The horses
were purchased as experimental animals from private
trainers. Six horses were electrically stimulated into AF
(the AF group) and three served as a time-matched,
sham-operated control group. All animals were deemed
healthy based on clinical examination including blood
analysis, and no abnormalities were found from ECG or
echocardiographic examinations at the time of inclusion.
Pacemaker implantation
Pacemaker implantation in horses has previously been
described (12). In this study dual-chamber pacemakers1
were implanted in nine horses for AF induction (AF
group) and electrophysiological studies (AF and control
group). The pacemakers were implanted in sedated
(0.01 mg/kg detomidine, 0.01 mg/kg butorphanol and
constant rate infusion of 1.0 mg/ml xylazine) standing
horses. The pectoral region was surgically prepared and
locally anesthetised before a 6–8 cm incision was made.
Through the cephalic vein two leads2 were advanced to
the heart and both were fixated in the right atrium.
Pacing ability, threshold, lead impedance and absence of
phrenic nerve stimulation were tested before and after
fixation. The leads were secured in the cephalic vein and
connected to the pacemaker which was placed in a sub-
cutaneous pocket distal to the incision. The incision was
sutured in three layers and the horses were treated with
antibiotics and non-steroidal anti-inflammatory drugs.
The surgery-time was between 60 and 150 min.
AF induction and study design
The study design is depicted in Fig. 1. AF was induced
by high-rate pacing from the pacemaker, pacing from
both leads at a rate of 170 min− 1 (with a delay between
the leads of 175 ms and 2.5 V @ 0.4 ms output) which
resulted in an atrial pacing rate of 340 min− 1. AF was
initiated by burst-pacing operated manually through the
pacemaker, which was continued daily (1–8 h per horse)
until sustained AF was achieved. During AF (in the
period of AF induction), the pacemaker was in an inhibi-
tory mode to automatically start pacing if the atrial rate
fell below 170min− 1, thus ensuring a minimum atrial
rate of 170 min− 1 at all times. The horses were con-
stantly monitored with ECG during AF induction, except
for a few hours per day, when they were allowed to walk
freely in the paddock. The pacemaker was turned off
after the horses had been in self-sustained AF for more
than 24 h.
Total AF durations were calculated from the surface
ECG, and all AF episodes of more than 10 min were in-
cluded. Episodes shorter than 10 min, burst-pacing and
pacemaker activity were not included. If the horses
spontaneously cardioverted to SR in the paddock (when
not equipped with an ECG) or at night (after dislodging
the electrodes), these periods were registered as uncer-
tain AF and were not included in the total AF duration.
To investigate the effect of both short- and long-term
AF on atrial remodelling, the procedures described
below were performed 3, 9, 27 and 55 days (procedure
days) after pacing was initiated. Baseline measurements
were obtained on day 0 before pacing was initiated (SR
measurements) and on day 1 (AF measurements). If the
horses were not in AF on the procedure days, the pace-
maker was turned off and the procedures were per-
formed in SR. To study the effect of remodelling on
pharmacological cardioversion, intravenous flecainide3
(2 mg/kg, rate 0.2 mg/kg/min) was administered on each
of the procedure days. Flecainide was chosen for cardio-
version as it previously has been studied in horses, it is
used in the clinic to treat paroxysmal AF and has a short
half-life (7). The pacemaker was turned off at least 30
min before flecainide infusion began to avoid that spon-
taneous cardioversion was attributed to the effect of fle-
cainide. A detailed description of the effects of flecainide
can be found elsewhere (13). At the end of each proced-
ure day, AF was re-induced following the same induc-
tion protocol as described above.
1AssurityTM MRI 2272, St. Jude Medical, St. Paul, MN
2Tendril STS Pacing Leads 100 cm, St. Jude Medical, St. Paul, MN 3TambocorTM, Meda A/S, Allerød, Denmark
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Electrocardiographic parameters
During AF induction and throughout each procedure
day, the horses were equipped with a three-lead Holter
ECG4 with the electrodes placed as a modified base-apex
ECG (7). The ECGs from each procedure day were
manually analysed offline by a single observer; QRS dur-
ation and QT interval were measured and averaged over
five consecutive beats and HR was averaged over 10
beats. QT measurements were adjusted beat-to-beat ac-
cording to species specific HR (QTc), as previously de-
scribed (14).
Atrial fibrillatory rate
Atrial fibrillatory rate (AFR) is a non-invasive measure-
ment of atrial remodelling, and is inversely proportional
to atrial fibrillation cycle length (AFCL) (15). AFR was
calculated from a 15-min surface ECG recording of AF.
ECG analysis including QRST cancellation and AFR cal-
culation was performed using the Cardiolund AFR
Tracker software5 (16).
Functional studies
Echocardiographic examinations were performed to
quantify left atrial and ventricular size and function. All
echocardiographic examinations were performed using a
portable Vivid I ultrasound system with a 3.1MHz
phased array transducer6 at rest and without sedation, as
previously described (17). Echocardiographic examina-
tions were performed before pacemaker implantation, at
baseline and on all procedures days (before, days 0, 1, 3,
9, 27 and 55) in both SR and AF when possible. Horses
in the AF group were examined in AF before administra-
tion of flecainide, and an additional examination was
performed if they cardioverted to SR after flecainide
treatment. Assessment of ventricular size and function
was performed from the examinations obtained in AF
while assessment of atrial size and function was per-
formed from the SR examinations as the left atrial
fractional area change measurements only can be ob-
tained in SR. Horses in the control group were examined
before flecainide administration. Colour flow Doppler
was used to assess valvular competences. Analysis was
performed offline7 by a single observer and two-
dimensional echocardiography (2D) and anatomical M-
mode (AMM) were used to assess the left atrial (LA)
and left ventricular (LV) size and function. Values are
reported as the average of three non-consecutive cardiac
cycles. Ventricular measurements are described in the
Additional file 1. Two-dimensional echocardiographic
variables for the assessment of LA size and function
were measured as follows: left atrial area at mitral valve
closure (LAAmin), left atrial area at onset of the P wave
(LAAa), left atrial area at mitral valve opening (LAAmax),
left atrial diameter at mitral valve opening (LAD), pas-
sive left atrial fractional area change (LA-Facpassive = (
LAAmax – LAAa) / LAAmax), active left atrial fractional
area change (LA-Facactive = (LAAa – LAAmin) / LAAa)
and total left atrial fractional area change (LA-Factotal =
LAAmax – LAAmin) / LAAmax) (18). Valvular insuffi-
ciency was classified as: none, clinically insignificant,
mild, moderate or severe (19).
Structural studies
The horses were euthanized between 58 and 63 days
after AF initiation by bolt-stunning, and cardiac tissue
was harvested for microscopy and quantitative polymer-
ase chain reaction (qPCR, described in Additional file 1:
Table S1) from the left atrial appendage (LAA), right
atrial appendage (RAA) and right ventricle (RV). Biop-
sies for microscopy were sliced (4 μm) and stained with
Picro-Sirius Red. Detailed information about the prepar-
ation of the tissue can be found in the Additional file 1.
Full biopsy sections were scanned, using a ZEISS Axios-
can slide scanner equipped with a 20x, 0.8 NA object-
ive.8 Scanned images were analysed with the software
ZEN 2.3 Blue edition9 in combination with the extension
Fig. 1 Study design. Study start at day 0, three weeks after pacemaker implantation. Baseline measurements were performed in sinus rhythm
(baseline SR) before atrial fibrillation (AF) induction and 24 h after pacing was initiated (day 1, baseline AF). Pacing continued until self-sustained
AF. Experimental protocol included electrocardiography (ECG), echocardiography, atrial fibrillatory rate recordings (AF group) and flecainide
administration. Cardiac tissue was harvested at the end of the study
4Televet 100, Telemetric ECG, Kruuse A/S, Langeskov, Denmark
5Cardiolund AFR Tracker software, cardiolund.com, Lund Sweden
6Vivid I, 3S Phased Array transducer, GE Healthcare, Horten, Norway
7EchoPAC PC, GE Healtcare, Horten, Norway
8Axio Scan Z1 slide scanner, Zeiss, Oberkochen, Germany
9ZEN 2.3 Blue edition, Zeiss, Oberkochen, Germany
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software ZEN Intellesis,10 which was used for image seg-
mentation to distinguish between background, muscle
and collagen. We applied two approaches for collagen
assessment. First, the full sections including large vessels,
epi- and endocardial tissue were analysed. Second, quan-
tification of interstitial fibrosis, where three areas from
each section containing either high amounts (interstitial-
max) or low amounts (interstitialmin) of collagen between
the cardiomyocytes were chosen, by eye and blindfolded
to the observer, and analysed as the average of intersti-
tialmin and interstitialmax.
Data analysis
Investigators were blinded to the group allocation and
procedure day throughout all analyses. Data analyses
were performed using Microsoft Excel11 and GraphPad
Prism.12 Changes in AFR and other ECG parameters be-
tween baseline and day 55, were assessed using student’s
t-tests where paired analysis were performed when ap-
propriate. Difference in fibrotic area and ion channels
expression (measured with qPCR) between AF and con-
trol were also assessed using student’s t-test. The qPCR
data were subsequently Bonferroni corrected. Echocar-
diographic data were compared to baseline measurement
with a one-way ANOVA followed by Dunnett’s post hoc
test for multiple comparisons. Data are presented as
mean ± SD and p ≤ 0.05 was considered significant.
Results
All horses completed the study period of 55 days. One
control horse developed non-cardiac-related colic and
could not participate on procedure day 3. After the
study period (day 59), cardioversion was attempted in
horse #1 with an additional dose of flecainide 10 min
after the first dose. The horse developed ventricular fib-
rillation and was not included in the molecular studies.
AF induction
All horses were continuously paced into self-sustained
AF until they no longer spontaneously cardioverted to
SR. The pacing time required to achieve self-sustained
AF varied among horses (18 ± 9.9 days, range 8–36 days).
AF stability increased over time for all horses; at the be-
ginning of AF induction, burst-pacing only resulted in
short AF episodes, but as pacing continued, longer AF
episodes occurred and eventually only a small number of
burst-pacing sessions were needed for AF to become
sustained (Fig. 2, panel C). The AF became less orga-
nized over time as it developed into more stable AF (Fig.
2, panel E and F). In contrast, no ECG changes were
observed in the control group between day 0 and day 55
(Fig. 2, panel A + B). Total AF duration ranged from 15
to 46 days (37 ± 11 days), and the AF burden for each
horse is illustrated in Fig. 3. The total duration of un-
known AF was on average 2.4 days per horse and was
not included.
Electrical remodelling
ECG changes
There was a trend towards an increased HR in the AF
group from day 0 (measured in SR) to day 55 when the
horses were in AF (HR day 0: 42 ± 13min− 1, HR day 55:
64 ± 20min− 1, p = 0.07). No difference in HR was ob-
served for the control group (HR day 0: 46 ± 10.2min− 1,
day 55: 42 ± 7min− 1, p < 0.05). No changes in QRS or
QTc duration were observed in any of the groups (p <
0.05). In the AF group, QRS duration was 103 ± 5ms on
day 0 and 100 ± 7ms on day 55. In the control group,
QRS duration was 93 ± 3 on day 0 and 92 ± 6 on day 55.
Mean QTc duration was 442 ± 38ms on day 0 and 441 ±
23ms on day 55 for the AF group and 438 ± 1ms on day
0 and 458 ± 10ms on day 55 for the control group.
Atrial fibrillatory rate
On day 1 (24 h after pacing was initiated), AFR was
299 ± 33 fibrillations per minute (fpm; range 239–323
fpm). The AFR increased during the study (apart from
day 3 when only two horses were in stable AF) and was
significantly higher on day 55 compared to day 1 (mean
AFR on day 55: 376 ± 12 fpm, range 362–394 fpm, p <
0.01, Fig. 4).
Ion channel expression
No significant changes in ion channel expression were
found for any of the genes (SCNA5, CACNA1C,
KCND3, KCNIP2, KCNA5, KCNH2, KCNQ1, KCNJ2,
KCNJ3, KCNJ5 and KCNN1–3.) between the AF and
control horses. Expression levels for each gene are pre-
sented in Additional file 1: Fig. S1.
Functional remodelling
Offline assessment of echocardiographic image and data
quality led to the exclusion of ventricular measurement
obtained in AMM for two horses from the AF group (on
day 1 and 55), and ventricular measurement obtained in
2DE for 1 horses in the AF group at day 55 and for atrial
images in one horse during AF at day 1.
From the echocardiographic examinations performed
in SR after cardioversion with flecainide (AF group) we
found that the left atrial area (LAAmin) significantly
increased after day 9 (p < 0.01, Fig. 5) compared to base-
line while no significant changes were observed for
LAAmax or LAD. The LA-Facactive significantly decreased
after day 3 (p < 0.01, Fig. 5) while no significant changes
10ZEN Intellesis, 2017, Zeiss, Oberkochen, Germany
11Microsoft, Redmont, 2016, USA
12GraphPad Software, San Diego, CA, USA
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were observed for LA-Facpassive but a tendency for LA-
Factotal was found at several time points and showed sig-
nificant difference at day 27 (p < 0.01). No differences
were observed between examinations performed before
pacemaker implantation and at baseline (after pace-
maker implantation, before induction of AF). Before car-
dioversion with flecainide the horses in the AF group
had an echocardiographic examination while in AF. Data
from these examinations revealed a significant enlarge-
ment of the LAAmin and LAAmax between baseline (AF
baseline = day 1) and day 55 (p < 0.01). No changes in
LAD or LA-Factotal were observed. Measurement of
LAAa, LA-Facactive and LA-Facpassive were not possible as
no P wave was visible during AF. We observed no
changes in either atrial size or function in the control
group (Fig. 5 and Additional file 1: Table S2). Measure-
ments of atrial size and function before the pacemaker
was implanted, at baseline, during the AF episodes and
after cardioversion are illustrated in Additional file 1:
Table S2.
Colour flow Doppler revealed a moderate tricuspid
valve insufficiency in one horse at inclusion that did not
progress during the study. Several horses had mild and
clinically insignificant valve insufficiencies. None of the
horses developed valvular insufficiencies beyond the
“mild” category throughout the study.
To study ventricular remodelling and monitor signs of
heart failure, LV size and function were in each group
assessed during the study. No differences were observed in
the AF or control groups during the study period (p >
0.05). Results are displayed in Additional file 1: Table S3–4.
Cardioversion to sinus rhythm
Results on cardioversion rates with flecainide have previ-
ously been published (13). Briefly, one horse was in
stable AF on procedure day 3, and cardioverted 3 min
Fig. 2 ECG traces during the study. A: Control horse in SR at day 0 and at day 55 (B). C: Manual burst-pace at day 0 resulted in short AF episodes
followed by SR. Arrow head indicate the first P wave after spontaneous cardioversion. D: Pacemaker driven atrial rhythm of 170 min− 1 (352 ms)
with intermittent AV block. E and F: One horse in AF at day 1 and day 55, respectively. Note the faster fibrillatory rate at day 55 (F). Paper speed
10mm/s, gain 10 mm/mv
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Fig. 3 AF burden. Total AF burden for individual horses. Black arrowheads indicate successful cardioversion to sinus rhythm after flecainide
administration. Grey arrowheads indicate unsuccessful cardioversion after flecainide administration. Pacing, AF episodes < 10 min and unknown
AF are not included
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after flecainide infusion was initiated. On day 9, 5/5
horses cardioverted (6–12min after flecainide infusion
began), on day 27, 5/6 horses cardioverted (4–62 min
after infusion began) and on day 55, 2/6 horses cardio-
verted (96 and 185min after infusion began, Fig. 3).
There was a correlation between the time from infusion
start until cardioversion to SR and the cumulative dur-
ation of AF (p < 0.001, R2 = 0.80) (13).
Structural remodelling
With the Picro-Sirius Red staining of connective tissue we
found a significantly increased collagen deposition in the
left atria in the AF group (compared to the control group)
for both the full LAA sections (p < 0.05, Fig. 6A, C) and
the analysis of interstitial fibrosis (p < 0.05, Fig. 6D, F).
There were no significant differences found for the full
RAA section (p = 0.14, Fig. 6B, C), although a tendency
was seen in the analyses of interstitial fibrosis (p = 0.06,
Fig. 6E, F). Quantification of collagen deposition of the RV
sections (Fig. 6C) showed no differences between the two
groups (p = 0.97).
Discussion
In this study, we have introduced a novel model of
chronic AF. We found that horses can be tachypaced
into to self-sustained AF and that AF promotes elec-
trical, functional and structural remodelling. Horses
spontaneously develop AF both with and without the
presence of underlying cardiac disease, which is why we
present the horse as a highly relevant animal model of
human AF. In order to study changes from early AF to
chronic AF, we included healthy horses, in which AF
was induced by tachypacing.
AF induction
The pacemaker ensured a constant rate between 170
and 340 min-1 in the atria, however this did not lead to
sufficient capture nor the development of self-sustained
AF. Burst-pacing was therefore introduced and com-
bined with pacing from the pacemaker it proved feasible
for inducing self-sustained AF in horses. Other animal
studies (8, 20) have used neurostimulators to automatic-
ally burst-pace the atria which is desirable as it is less
time-consuming for the operators and ensures a uniform
and a most likely faster AF induction. The pacing-time
required to achieve self-sustained AF varied among
horses, suggesting a variation in AF vulnerability. Atrial
pacing led to increased AF vulnerability and increased
AF duration in all horses; this is the main feature of
atrial remodelling where “AF begets AF” (2). One horse
(#6) required a particularly long pacing-time, which
could be attributed to its small size (408 kg), as AF is dif-
ficult to induce in small horses (11). Despite the pro-
longed period before persistent AF was induced in this
horse, intensive pacing did seem to remodel the heart, as
this horse could not be pharmacologically cardioverted
by flecainide on day 55.
Electrical remodelling
A number of studies on electrical properties in horses
with induced AF have been published (5, 7–9) and in
one of them, spontaneous cardioversion to SR allowed
refractory period measurements without drug interfer-
ences (8). The equine atrial refractoriness is rate-
dependent and decreases with AF (7–9) in a similar
way to humans (21), dogs (22), pigs (23) and goats (2).
Shortening of the refractory period allows more
Fig. 4 Atrial fibrillatory rate. Left: Example of spatiotemporal QRST cancellation: From the surface ECG (top trace), the software identifies the QRS
complexes. After QRST cancellation, only the atrial signal remains (bottom trace). Right: The course of AFR during the study. AFR increases
significantly (p < 0.01) from day 1 to day 55 consistent with atrial remodeling. n = 6 except day 3 (n = 2). Data are presented as mean ± SD. AFR =
atrial fibrillatory rate, fpm = fibrillations per minutes. Asterisks indicate statistical significance (p < 0.01)
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fibrillatory waves to co-exist, which further promotes
AF. In this study, we measured the rate of the fibrilla-
tory waves while the horses were in AF. Several studies
have validated AFR as a measurement of electrical re-
modelling (24–26), and this method allowed us to study
the progression of electrical remodelling non-invasively
and without drug interference. We found a significant
increase in AFR between day 1 and day 55, which is
representative of electrical remodelling. We have previ-
ously studied AFR in horses with both short-term in-
duced AF and spontaneous persistent AF (26). Similar
to the findings in this study, the AFR in horses with in-
duced short-term AF was lower (269 ± 36 fpm) com-
pared to horses with spontaneous persistent AF (364 ±
26 fpm) (26). These values correspond well with AFR
values in patients with paroxysmal and persistent AF,
respectively (25, 27).
Electrical remodelling also describe changes in the
genes encoding ion channels during AF. In this study,
no difference in ion channel expression was observed
between the AF and control group. Other studies
have found a down-regulation in the L-type Ca2+
channel, the α subunit of cardiac Na+ channels and
Kv4.3 channel (28, 29), however, as these analyses are
underpowered similar conclusions cannot be made
from the present study.
Functional remodelling
Atrial fibrillation is also known to cause atrial enlargement
and contractile dysfunction that can persist several days
after cardioversion (30). In patients, atrial contractile dys-
function, also known as “atrial stunning”, is considered an
important risk factor for thromboembolisms (31). In this
study, we observed a significant reduction in atrial
Fig. 5 Functional remodelling of the left atrium. Echocardiographic evaluation of atrial size and function. Top panel illustrates the left atrial active
fractional area changes (LA-Facactive) in the AF group (left) and in the control group (right) before pacemaker implantation (before), at baseline
(day 0) and on each procedure day (day 3, 9, 27, and 55). Bottom panel illustrates the left atrial area at mitral valve closure (LAAmin). Asterisk
indicate significant differences from baseline (*, p < 0.05, **, p < 0.01, ***, p < 0.001). All echocardiographic examinations were obtained in SR after
cardioversion with flecainide (AF group). Data are presented as mean ± SD
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function (LA-Facactive) three days after AF induction was
initiated. Atrial remodelling has also been documented in
dogs after 6 weeks of continuous pacing (22) and a study
on instrumented goats tachypaced into AF, showed that
atrial function was reduced already after 5min of AF and
that the reduction increased with AF duration (32). Simi-
lar results have been described for horses with spontan-
eous (18) and induced AF (8, 33).
Fig. 6 Fibrosis. Picro-Sirius Red staining of cardiac tissue from the AF group (n = 5) and the control group (n = 3). A + B: Representative
images of left atrial appendage (LAA, panel A) and right atrial appendage (RAA, panel B) sections, respectively. Fibrosis is stained red.
C: Quantification of Picro-Sirius Red positive areas for full sections of the three regions: LAA, RAA and right ventricle (RV). Collagen
was significantly increased in the LAA in the AF group (black) compared to the control group (grey). D + E: Representative images
showing areas of interstitial fibrosis for LAA (D) and RAA (E). F: Quantification of Picro-Sirius Red positive areas showed a significant
increase in interstitial fibrosis for the AF group in the LAA compared to the control group. Sections for RV not shown. *p < 0.05. Scale
bar = 500 μm in (A and B) and 100 μm in (D and E)
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Ventricular function
Atrial fibrillation is associated with impaired ventricular
function and heart failure is a common comorbidity in
AF patients. Although not fully elucidated, this is likely
to be the result of a tachycardia-induced cardiomyopathy
caused by a persistently increased HR (34). In human
patients, the increased HR is often managed with rate-
control drugs such as beta-blockers (1). Other animal
models also have increased HR, and these are often
treated medically with digoxin, or surgically with an AV
nodal ablation (20). Horses have a high vagal tone, and if
they develop persistent AF they usually have a normal to
slightly increased HR (35). In accordance with this, we
found no significant difference in HR between the AF
and control group. In addition, no changes in ventricular
size or function from the echocardiographic examina-
tions were found and no differences in ventricular fibro-
sis between control and AF group were observed. These
results are in accordance with observations from the
equine clinic, where horses with spontaneous AF rarely
develop heart failure without underlying cardiac disease
(18, 36). Tachycardia induced heart failure albeit medical
rate control has been shown in pigs and dogs, while
goats did not show signs of heart failure. Increased myo-
cardial fibrosis was also evident in the ventricles of the
pigs and dogs but not in the goats (20).
Cardioversion to sinus rhythm.
The success rate of medical cardioversion to SR de-
creases as AF progresses (1). A human clinical study previ-
ously reported that the cardioversion success rate
decreased from 86 to 22% if the patients treated with fle-
cainide had been in AF for longer than 10 days (37). We
found similar results in this study, as the cardioversion
success rate fell from 100% on days 3 and 9 to 33% on day
55. This suggests that the horse could be an interesting
model for testing novel antiarrhythmic drugs, as it seems
that the response to medical treatment is comparable.
Structural remodelling
In addition to electrical and functional remodelling, AF
is also known to cause structural remodelling, which in-
cludes hypertrophy of the cardiomyocytes, myolysis, al-
terations in connexin expression and interstitial fibrosis,
all of which increase conduction heterogeneity and sup-
port the maintenance of AF (30, 38). To our knowledge,
this is the first study to compare structural remodelling
in horses with and without AF and we found signifi-
cantly increased amounts of collagen in the AF group.
The difference between groups was more pronounced in
the left atrium compared to the right atrium, where only
a tendency was present. Several studies in both human
patients (39) and animal models (20) show an increase
in collagen as a consequence of AF. The literature seems
to agree on increased fibrosis in the left atrium in
patients with AF, yet there are mixed results regarding
right atrial fibrosis (40). Some studies report an equal
amount of fibrosis in both the left and right atrium,
while other studies report similar findings as this study,
where less fibrosis was observed in the right atrium
compared to the left (41–43). Atrial fibrosis increases
with age which have been suggested to be a contributing
factor to the increased AF burden in the aging popula-
tion (44). In this study two out of the three control
horses were above the age of 15 years which might have
caused an increase in fibrosis in the control group.
Limitations
This study is limited by the relatively low number of ani-
mals included. The small sample size is strengthened by
the longitudinal design of the study which facilitates re-
peated measurements, however, both the AF and SR
measurements holds several missing values. The missing
AF values are attributed to the prolonged AF induction,
which could have been avoided by continuous burst-
pacing. Sinus rhythm measurements were limited by the
attenuated ability of flecainide to cardiovert longstanding
AF. Future studies should consider either a more potent
drug than flecainide or electrical cardioversion in order
to obtain SR measurements. AFR only provides a sum-
mary of the atrial activity and local heterogeneity cannot
be captured with this method. Technical errors pre-
vented us from assessing local changes in AFCL and
atrial refractoriness. Future studies should explore endo-
and epicardial atrial recordings and mapping of fibrilla-
tion patterns.
Conclusion
In this study, we have described a model for chronic
AF in horses which are naturally predisposed to AF.
We observed electrical remodelling (as AFR increased
during the study period), functional remodelling (de-
scribed by atrial enlargement and reduced left atrial
fractional area change), and structural remodelling (as
the atria in the AF group were more fibrotic than in the
control group), which are findings likely to contribute
to the maintenance of AF. In accordance with this, a
decrease in the efficacy of the anti-arrhythmic drug fle-
cainide was observed. No functional remodelling of the
ventricles or signs of heart failure were observed. This
makes the model interesting for long-term AF studies.
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